The tumor necrosis factor (TNF) receptor family are ligand-regulated transmembrane proteins that mediate apoptosis as well as activation of the transcription factor NF-kB. Exogenous expression of DR6, a recently identi®ed member of the TNF receptor family, induced apoptosis in untransformed or tumor-derived cells and the apoptotic function of DR6 was inhibited by coexpression of Bcl-2, Bcl-x L or the inhibitor-of-apoptosis (IAP) family member, survivin. Expression of a dominant negative mutant of FADD failed to protect from DR6-mediated apoptosis indicating that unlike TNFR1 and Fas, DR6 induced apoptosis via a FADDindependent mechanism. Despite the ability of exogenous DR6 expression to induce apoptosis, DR6 mRNA and protein were found to be elevated in prostate tumor cell lines and in advanced stages of prostate cancer. Analysis of several anti-apoptotic proteins revealed that Bcl-x L levels and serine 32 phosphorylation of IkB, the natural inhibitor of NF-kB, were similarly elevated in cells expressing high levels of DR6, suggesting that NF-kBregulated survival proteins may protect from DR6-induced apoptosis and that DR6 is a target of NF-kB regulation. Treatment of LnCAP cells with TNF-a resulted in increases in both DR6 mRNA and protein levels, and this induction was suppressed by inhibitors of NF-kB. Similarly, treatment of cells expressing high levels of DR6 with indomethacin and ibuprofen, compounds also known to perturb NF-kB function, resulted in a dose-dependent decrease in DR6 protein and mRNA levels. These results demonstrate that TNF-a signaling induces the expression of a member of its own receptor family through activation of NF-kB. Oncogene (2001) 20, 7965 ± 7975.
Introduction
Apoptosis is an active process of cell death required for the normal development and homeostasis of multicellular organisms (Jacobson et al., 1997) . Apoptosis is characterized morphologically by changes in cellular structure that include membrane blebbing, loss of adhesion and intracellular contacts, chromatin condensation and nuclear fragmentation, and the dismantling of the cell into apoptotic bodies (Wyllie, 1980) . Over the past decade a broad spectrum of proteins have been identi®ed that positively or negatively in¯uence apoptosis. Disruption of this highly regulated process can lead to pathological conditions including cancer, autoimmune disorders, neurodegenerative diseases, sustained viral infections, and developmental disorders (Granville et al., 1998) .
Apoptosis can be triggered by a family of structurally similar receptors of the tumor necrosis factor (TNF) receptor family which include TNFR1, Fas/Apo-1/CD95, DR3, DR4, DR5, and DR6 (Nagata, 1997; Chaudhary et al., 1997; Pan et al., 1997 Pan et al., , 1998 . These proteins are characterized by a cysteine-rich, extracellular domain and a conserved intracellular death domain. In general, these receptors are activated by either soluble or membranebound cytokines, TNF-a, Fas ligand (FasL), and TRAIL, which leads to oligomerization of the receptor and subsequent recruitment of death domain contain adaptor molecules (Nagata, 1997) . In the case of Fas, binding of FasL initiates recruitment of the adaptor molecule, FADD, to the receptor complex via death domain interactions, which in turn recruits the initiator caspase, caspase-8, to the receptor complex through a homophilic interaction between the death eector domains present in FADD and the pro-domain of caspase-8. Caspase-8 recruitment/oligomerization promotes autocleavage of the enzyme resulting in its activation and subsequent initiation of a cascade of cleavage events mediated by downstream eector caspases such as caspases-3 and -7 to execute apoptosis (Thornberry and Lazebnik, 1998) . A similar mechanism for TNF-a signaling is observed but requires an intermediate adaptor molecule, TRADD, which links the receptor to the FADD-pro-caspase-8 complex (Thornberry and Lazebnik, 1998) .
In addition to the apoptotic response elicited by TNF-a, the cytokine also induces a distinct pathway leading to the activation of the transcription factor NF-kB (Hsu et al., 1996) . For TNFR1 and the related receptor TNFR2, receptor activation promotes the binding of TRAFs and subsequent recruitment of the serine/threonine kinase NIK via interaction with TRAF2 (Hsu et al., 1996; Malinin et al., 1997) . This TNF receptor/TRAF interaction leads to the activation of IkB kinase and phosphorylation of IkB at serine residues at positions 32 and 36 (Malinin et al., 1997; Woronicz et al., 1997; ReÂ gnier et al., 1997) . The serine phosphorylation of IkB triggers its degradation via the ubiquitin pathway and results in an increase in NF-kB nuclear translocation and transcriptional activity (Baeuerle and Baltimore, 1996) . While NF-kB may have both pro-and anti-apoptotic activity depending on cellular context, transcriptional regulation by NFkB can suppress TNF-a-mediated apoptosis and activation of NF-kB may be the dominant pathway following TNF-a treatment (Wang et al., 1996; Van Antwerp et al., 1996; Beg et al., 1996) . A number of genes implicated in the pro-survival eects of NF-kB have been identi®ed as transcriptional targets of this protein including members of the TNF receptor association factor family (TRAF1 and TRAF2, ), Bcl-2 family (Bcl-x L and A1/B¯-1, (Lee et al., 1999) ) and the inhibitor-of-apoptosis protein (IAP) family (c-IAP1, c-IAP2, and XIAP, Stehlik et al., 1998) ). In contrast to these observations, much less is known regarding the transcriptional changes associated with the pro-apoptotic function of NF-kB.
Activation of the apoptotic function of TNF receptors oers potential therapeutic use in cancer because these receptors can trigger apoptosis in a variety of tumor cells and do not require p53 function for anti-tumor cell activity (Tartaglia et al., 1992) . To evaluate the utility of the recently identi®ed TNF receptor member, DR6, as a potential therapeutic target, we examined the signaling properties of the receptor in transformed cells and pro®led its expression in a panel of human tumor-derived cells. Surprisingly, a dramatic increase in DR6 mRNA and protein was observed in several prostate cell lines and late stage primary tumors compared to normal tissue and less transformed cell lines. This expression of DR6 was correlated with an increase in the expression of a NF-kB target gene, the anti-apoptotic protein Bcl-x L , but also with an increase in phosphorylated, inactive IkB, a negative regulator of NF-kB function. Further studies revealed that DR6 mRNA and protein levels were up-regulated by TNF-a treatment and this induction was suppressed by inhibition of NF-kB. These ®ndings indicate that TNF-a-signaling through NFkB activation positively regulates the expression of DR6, a TNF receptor family member with distinct apoptotic signaling properties.
Results

Tumor cell expression and chromosomal localization of DR6
The attractiveness of members of the TNF family as chemotherapeutic agents hinges on their ability to selectively target cognate TNF receptors in malignant tissue without inducing apoptosis of normal cells (Bonavida et al., 1999) . To assess the expression of DR6 in tumor cells and explore its potential role in tumor development, we examined the expression of DR6 mRNA by Northern blot analysis of RNA isolated from human tumor cell lines derived from lung, colon, breast and prostate tumors as well as from several non-transformed counterparts. DR6 mRNA was expressed predominantly as a *4 kb mRNA with most cells also expressing a minor *4.4 kb transcript ( Figure 1a ). Analysis of lung and colorectal tumor cell lines revealed that DR6 was expressed at moderate levels in the majority of these tumor cell lines. DR6 mRNA was also detectable in the breast, although at slightly lower levels compared to lung and colon tumor cell lines and tissue. The expression of DR6 mRNA was not signi®cantly altered in either lung, colorectal, or breast tumor cells compared to matched nontransformed cell lines or normal tissue, suggesting alterations in DR6 expression are not associated with the cancerous progression of these cells.
In contrast to the other tumors tested here, DR6 mRNA was expressed signi®cantly higher in several prostate tumor cell lines compared to normal tissue and the modestly transformed tumor cell line, LnCAP ( Figure 1a) . In addition to the *4 kb DR6 transcript, a *3.5 kb DR6 mRNA was also abundantly expressed in a subset of the prostate tumor cell lines suggesting the presence of alternate form of DR6 message. Extensive RT ± PCR and sequence analysis of DR6 cDNA prepared from cells expressing the *3.5 kb DR6 mRNA revealed no alterations in the DR6 coding region indicating that this transcript may dier in its untranslated regions (data not shown).
As DR6 mRNA was detected in RNA from prostate tissue ( Figure 1a ) and in normal prostate epithelium by in situ hybridization (data not shown), the expression of DR6 protein was evaluated further in various stages of prostate cancer by anti-DR6 immunostaining of tissue microarray containing normal and malignant tissue. Increased DR6 expression was observed in tissue from late stages of prostate cancer (Figure 1b) as well as breast cancer (data not shown) compared to normal tissue. Expression was particularly high in prostate tumors with a Gleason score of 9 through 10 compared with prostate tumor tissue obtained from individuals with early stage disease. The elevated expression of DR6 in advanced prostate adenocarcinoma suggests that DR6 signaling correlates with malignant progression of this tissue.
To determine if DR6 was associated with genetic alterations accompanying prostate cancer, FISH analysis was performed to determine the chromosomal location of DR6. Human metaphase chromosome spreads were prepared from normal lymphocytes and hybridized with a¯uoresceinated digoxigenin-labeled human DR6 genomic BAC clone. DR6 was present at identical sites on chromosome 6 in all samples analysed corresponding to band 6p21.1 (Figure 1c) . + RNA (2 mg/lane) was isolated from human lung tumor (HA146, HA188, #1299, SW1271, and HA1182), colon tumor (LS180, HA1233, COLO205, SW480, HCT116, and HA1298), breast tumor (MCF7, MCF10, MDA-MB 231, ZR75-1, and MDA-MB-468) and prostate tumor (PC3-ATCC, PC3-P, PC3-BM, and DU145). In addition, adult tissue (lung, colon, breast, and prostate) and untransformed cell lines from lung (SAEC), colon (HT29) and breast (B5/589), a normal human ®broblast cell line (M426) and a modestly transformed prostate cell line (LnCAP) were included from comparison. All of the blots were hybridized to DR6 cDNA probe and then stripped and rehybridized with a probe to b-actin. The absence of chromosomal alterations at 6p21 in major solid tumors suggests that increased DR6 mRNA in prostate tumor cells may result from an epigenetic mechanism.
Apoptotic signaling by DR6
Exogenous expression of DR6 was found previously to induce apoptosis in the cervical carcinoma cell line, HeLa, but not in the mammary carcinoma cell line, MCF7 suggesting cell type dierences in DR6 signaling to induce apoptosis (Pan et al., 1998) . To explore the mechanism of DR6-mediated apoptosis in more detail we analysed its apoptotic function in several cell lines including HeLa, NIH/3T3 and LnCAP. The ability of DR6 to induce apoptosis was monitored using a GFP reporter that was co-expressed with DR6. The loss of GFP by DR6-expressing cells directly correlated with annexin-V staining, a biochemical parameter of apoptosis (data not shown). DR6 was able to induce apoptosis in HeLa, NIH3T3, and LnCAP cells ( Figure  2a ). DR6-mediated apoptosis could be inhibited by the anti-apoptotic proteins Bcl-2 and Bcl-x L , as well as by survivin, which has been shown to inhibit apoptosis by many stimuli through inhibition of caspases-3 and -7 (Tamm et al., 1998) . Similarly, DR6 activity was suppressed by the general caspase inhibitor Z-VAD ( Figure 2a ). However, dominant-negative FADD (FADD-DN) had no eect on DR6 in any of the cell lines, suggesting that signaling via DR6 diers from that of the related receptors Fas and TNFR1 ( Figure  2a ).
Further dissection of the DR6 pathway was performed using more speci®c peptide inhibitors of dierent caspases (Thornberry et al., 1997) . Inhibition of DR6 was observed by Z-DEVD, an inhibitor of caspases-3, -6, -7, -8, and -10, as well as by the caspase-8 inhibitor, Z-IETD, and the caspase-2 inhibitor, Z-VDVAD ( Figure 2b ). However, the caspase-6 inhibitor, Z-VEID ( Figure 2c ) was unable to protect from DR6-mediated apoptosis. Together, these data suggest that while the signaling of Fas and TNFR1 involves recruitment of FADD which acts to directly activate caspase-8 (Hsu et al., 1996) , or recruit RIP and RAIDD to activate caspase-2 (Duan and Dixit, 1997), DR6-mediated apoptosis may require both of these caspases but their activation is independent of FADD. As DR6 expression induced apoptosis of a variety of cell types, it was surprising that the PC3 and DU145 cells expressed the protein at such high levels. To rule out the possibility that the DR6 protein expressed by PC3 and DU145 cells was impaired and could not elicit an apoptotic response, the apoptotic eects of DR6 ectopic expression on PC3 and DU145 cells were examined. Unlike LnCAP cells, which displayed a dramatic apoptotic response to DR6 expression after 48 h, DR6 expression in PC3 and DU145 cells did not signi®cantly induce apoptosis in these cells (Figure 2c) . Interestingly, these cells are remain sensitive to the death receptor ligand, TRAIL, thereby illustrating dierences in signaling between TRAIL and DR6 (Munshi et al., 2001; Rokhlin et al., 2001) . The inability of endogenous or heterologous DR6 expression to induce apoptosis of PC3 and DU145 cells suggests these cells possess a mechanism(s) to override the eects of this apoptotic protein.
Elevated expression of DR6 protein is associated with Bcl-x L and phosphorylated IkB
Although heterologous DR6 expression induced apoptosis in a variety of cell types, its expression was highly elevated in some prostate cancer cell lines suggesting these cells were refractory to DR6-induced apoptosis. To investigate this observation in more detail, the levels of DR6 protein as well as several anti-apoptotic proteins shown to inhibit DR6-apoptosis were examined in prostate tissue and in LnCAP, DU145 and PC3 cell lines. An anity puri®ed polyclonal antibody raised against the cytoplasmic domain of DR6 was used to con®rm the elevation of DR6 in these cells. Anity puri®ed anti-DR6 antibodies detected a prominent band at *75 kDa, consistent with the size predicted from DR6 cDNA, on Western blots of lysates prepared from PC3 cells (Figure 3a ). In addition, lower molecular weight bands migrating as a doublet at *68 kDa were also detected by this antibody. The detection of all three proteins was eectively blocked by pre-incubation of the DR6 antibody with recombinant DR6 protein but not the related family member, p75 NGF receptor, suggesting that these lower bands may be the products of the proteolytic processing of DR6. Nonetheless, comparison of DR6 levels in the prostate cell lines revealed that DR6 protein was dramatically increased in DU145 and PC3 as compared to LnCAP or normal prostate tissue and displayed an expression pattern consistent with the DR6 mRNA levels observed in these cells (see Figure 1a) .
Since Bcl-2, Bcl-x L and survivin were shown to inhibit DR6-mediated apoptosis, we explored the possibility that elevated levels of these proteins can contribute to the survival of PC3 and DU145 cell lines in the presence of high levels of DR6. Of the proteins examined, Bcl-x L levels were signi®cantly elevated in DU145 and PC3 cells as compared to LnCAP and normal prostate tissue (Figure 3a) . In contrast, no similar elevation was observed in the expression of either Bcl-2 or survivin in these cells. While not represented here, Bcl-2 could be detected upon longer exposure consistent with previous reports of low levels of Bcl-2 in these prostate cell lines (Munshi et al., 2001; Rokhlin et al., 2001) . The results suggest that increased levels of Bcl-x L may contribute to the survival of the transformed prostate cell lines and balance the consequence of elevated DR6 levels.
Expression of DR6 and other TNFR family members have been shown to activate NF-kBdependent transcription (Pan et al., 1998) . To investigate whether the high levels of DR6 in PC3 and DU145 cells were associated with an increase in the activity of the NF-kB pathway, the levels and phosphorylation state of IkB-a, the inhibitor of NFkB, were also examined. While the levels of IkB-a were equivalent between the three cell lines, an increase in the inactive, serine 32-phosphorylated form of IkB-a was observed in PC3 and DU145 compared to LnCAP cells suggesting that the NF-kB pathway is constitutively active in these cells. In line with these observations, the increase in IkB-a phosphorylation was correlated with a decrease in androgen receptor which has previously been shown to be downregulated in response to NF-kB activation (Supakar et al., 1995) . These results suggest that activation of NF-kB in PC3 and DU145 cells can protect from DR6-induced apoptosis and that DR6 gene expression may be regulated by this transcription factor.
TNF-a up-regulates DR6 via NF-kB
To further explore the possibility that NF-kB could induce DR6 expression, LnCAP cells were treated with the NF-kB activating cytokine, TNF-a. Consistent with this hypothesis, there was a time-dependent increase in DR6 protein accumulation triggered by TNF-a ( Figure  4a ). DR6 levels began to rise at 8 h and continued to increase up to 24 h post-treatment. In contrast, the other TNF receptor ligands, TRAIL and FasL, had no eect on DR6 expression in LnCAP cells (Figure 4b ). These results are in agreement with the observations that unlike TNF-a, TRAIL and FasL have little eect on NF-kB activation and that FasL may even inhibitory activity on NF-kB (Nagata, 1997; Ravi et al., 1998; Yu et al., 2000) . TNF-a also displayed a more modest induction DR6 protein in an endothelial cell line but not in a hematopoetic derived TNF-a responsive cell suggesting the induction of DR6 displays tissue speci®city.
Next, to determine whether the induction of DR6 by TNF-a in LnCAP cells was due to NF-kB activation we treated the cell with a peptide inhibitor of NF-kB nuclear translocation, SN50. SN50, but not an inactive control peptide, inhibited TNF-a-mediated DR6 expression (Figure 5a ). Furthermore, treatment with the nonsteroidal anti-in¯ammatory drugs (NSAIDs), ibuprofen and indomethacin, which also inhibit NF-kB (Yamamoto et al., 1999; Palayoor et al., 1999) , suppressed DR6 accumulation in response to TNF-a (Figure 5a) . Similarly, ibuprofen and indomethacin led to a dose dependent decrease in DR6 in PC3 cells, in which DR6 was expressed abundantly (Figure 5b ). In addition, the observed changes in DR6 protein correlated with changes at the mRNA level as measured using TaqMan 1 RT ± PCR. A fourfold increase in DR6 mRNA was observed in LnCAP cells treated with TNF-a and this induction in DR6 mRNA was inhibited by SN50 (Figure 5c ). In PC3 cells expressing high levels of DR6, ibuprofen treatment signi®cantly decreased DR6 mRNA levels. Taken together, there results suggest that NF-kB plays a critical role in the transcription and expression of DR6, and that decreased NF-kB activity in progressed prostate cancer cells may lead to elevated levels of DR6. 
Discussion
Abnormalities in the signaling pathways leading to apoptosis are fundamental to the development and progression of cancerous cells. The death ligands and receptors of the TNF/TNFR family have emerged as attractive candidates for modulating tumor cell apoptosis based on their ability to bypass p53-dependent mechanisms in executing programmed cell death (Tartaglia et al., 1992) . We report that the new member of the TNFR family, DR6, induced apoptosis in a variety of cell types and this apoptotic activity was dependent on the levels of downstream anti-apoptotic proteins including the Bcl-2 and IAP family members, similar to other death domain receptors. In contrast, dominantnegative mutants of the TNFR1 and DR3 adaptor protein, FADD, had no eect on DR6-induced apoptosis in multiple cell types, suggesting that DR6 does not utilize the FADD adaptor molecule to couple to downstream apoptotic eector proteins such as the caspases. Similarly, DR4 and DR5 have also been shown to induce cell death independently of FADD (Pan et al., 1997; Sheridan et al., 1997; Marsters et al., 1996; Yeh et al., 1998) . Although the proteins which link DR4 and DR5 to downstream eectors are not known, the FADD-independent signaling of DR6 suggests this receptor may utilize the same adaptor molecules as DR4 and DR5. Although it is still unknown how these receptors propagate an apoptotic signal, the studies reported here with speci®c caspase inhibitors suggest that DR6 adaptor proteins couples to the activation of candidate caspases including caspases-2, -3, -7, and -8 to execute apoptosis.
The toxic eects of TNF-a and FasL on normal tissue (Bonavida et al., 1999) presents a major hurdle for modulating the TNF family apoptotic response as an approach for cancer therapy and highlight the need for the identi®cation of alterations in the TNFR pathway(s) that are speci®c to the tumor cell. For the Fas signaling pathway this issue is compounded further by the overexpression of FasL in many tumor cells resulting in the ability of these cells to evade immune responses similar to that observed for immune privileged sites (Nagata, 1997). In contrast, the TRAIL/Apo2L receptors, DR4 and DR5, have become attractive targets for cancer therapy based on the ®ndings that decoy receptors which antagonize DR4 and DR5 signaling are selectively expressed on normal cells thereby allowing tumor cell-speci®c apoptotic activity of TRAIL (Zhang et al., 1999; Sheikh et al., 1999) . Here we showed that DR6 expression is dramatically increased in cell lines derived from the prostate tumors, PC3 and DU145. It is not known whether decoy receptors for DR6 exist that can antagonize receptor function. Although we detect multiple DR6 transcripts in PC3 and DU145 cell lines, we could not identify DR6 transcripts which diered in their coding potential by PCR analysis of RNA from these cells. PC3 and DU145 cells were also resistant to the transient overexpression of DR6 suggesting that these cells have developed a mechanism to overcome the high levels of this death receptor. The up-regulation of the anti-apoptotic protein, Bcl-x L , in these cells may partly explain the resistance to DR6-mediated cell death as Bcl-x L could inhibit DR6-induced apoptosis in sensitive cells. An additional explanation for the resistance to DR6 apoptosis in PC3 and DU145 is the observed elevation of serine 32 phosphorylated IkB-a, negative regulator of NF-kB, and from the recent report of constitutive NF-kB activity in these cells (Palayoor et al., 1999) . Since NF-kB can regulate the expression of several anti-apoptotic genes such as c-IAP-1 and -2 as well as TRAF1 and -2, the upregulation of these factors by NF-kB could also counterbalance DR6 overexpression. Taken together these observations suggest that the tolerance to DR6 expression in DU145 and PC3 re¯ects the elevated activities of anti-apoptotic proteins such as Bcl-x L and NF-kB.
Evidence was presented that DR6 mRNA and protein were induced following stimulation with TNF-a, and that this could be blocked by inhibiting NF-kB transcription activity. Furthermore, NSAIDs, which are potent inhibitors of NF-kB signaling, were able to inhibit endogenous DR6 expression in PC3 cells. These results suggest that NF-kB is able to directly or indirectly regulate DR6 transcription. More direct evidence for the role of NF-kB should be The use of TNF-a as an anti-cancer agent is limited primarily by the ability of this cytokine to induce a lethal septic shock response resulting from constitutive NF-kB activity in tissues such as the vascular endothelium and macrophages (Tartaglia et al., 1992) . The ability of DR6 to stimulate NF-kB transcriptional activity (Pan et al., 1998) suggests that DR6 may contribute to the toxic in¯ammatory response of TNFa by amplifying the activity of the NF-kB pathway. In this regard it is interesting to note that the induction of DR6 by TNF-a was also observed in endothelial cells, a target cell population thought to underlie the toxic eects of TNF-a administration.
The consequence of TNF-a induction of DR6 in other tissues such as prostate is not known. Interestingly, the absence of androgen receptor (AR) expression in prostate cancer cell lines correlated with the increase in phosphorylated IkBa and constitutive NFkB activity (Palayoor et al., 1999) , consistent with reports that androgen receptor expression can be down-regulated in response to NF-kB (Supakar et al., 1995) . It is important to note that the DR6 induction by TNF-a was suppressed by synthetic androgenagonists but maintained in the presence of AR antagonists (unpublished observations) suggesting that AR activity is also important in regulating DR6 expression. Here we observed an increase in DR6 expression in advanced stages of prostate cancer Figure 5 DR6 expression is regulated by NF-kB and NSAIDs. (a) LnCAP cells were treated with TNF-a (10 ng/ml) for 18 h alone and with the inhibitor of NF-kB nuclear translocation, SN50 or a related inactive peptide, SN50m (50 mg/ml), or with the NSAIDs, ibuprofen (1 mM) or indomethacin (0.3 mM). Lysates (*250 mg) were prepared from the cells and DR6 protein levels were determined by immunoprecipitation and Western blotting using anity-puri®ed DR6 antibodies. Immunoglobulin heavy chain is indicated (IgH). (b) PC3 cells were incubated with the indicated concentrations (mM) of indomethacin or ibuprofen for 18 h and processed by Western analysis using anti-DR6 antibodies. Membranes were also reprobed with anti-actin antibodies to normalize DR6 protein expression. (c) LnCAP and PC3 were treated with TNF-a, active and inactive SN50, or ibuprofen (12 h) as indicated. TaqMan 1 RT ± PCR was performed for DR6 and normalized against GAPDH to determine the relative abundance of DR6 mRNA. Error bars indicate standard deviation (n=3) suggesting that the death receptor plays a role in the progression of the disease. In this regard it is interesting to note that high-grade prostate cancer has been associated with an increase in apoptosis (Johnson et al., 1998; Haussler et al., 1999) . As DR6 expression was elevated in other types of cancer, particularly in breast, it will be of interest to determine if DR6 signaling plays a more general role in cancer progression.
Materials and methods
Database searching and DR6 DNA constructs A DR6 cDNA was identi®ed by homology searches of a proprietary database (Incyte Pharmaceuticals, Palo Alto, CA, USA) using a conserved death domain sequence. A 1.8 kb cDNA encoding a death domain and signal peptide as well as containing 5' and 3' untranslated sequences was obtained from Incyte. A SpeI/NotI fragment of this cDNA containing the entire open reading frame was subcloned into the corresponding sites of pTracer-SV40 (Invitrogen, Carlsbad, CA, USA) which independently expresses the green¯uorescent protein (GFP) under control of the CMV promoter. The DR6 cytoplasmic domain was ampli®ed by the polymerase chain reaction using 5'-TTT AGA TCT CGG AAA AGC TCG AGG ACT CTGAAA AAG GGG (forward primer) and 5'-TTT CAA TTG CTA CAG CAG GTC AGG AAG ATC GC (reverse primer) derived from DR6 mRNA (Pan et al., 1998) . The product was digested with BamHI/EcoRI and ligated into the corresponding sites of pGEX6p-1 (Amersham Pharmacia Biotech, Piscataway, NJ, USA) for production of protein containing N-terminal GST moiety in-frame with 369 ± 655 amino acids of DR6 which used for antibody preparation and puri®cation. The identities of all the plasmid constructs was con®rmed by DNA sequencing from both strands.
Cell culture
Human lung, colon, breast and prostate tumor cell lines were obtained from ATCC (Rockville, MD, USA) and M426, PC3-P, PC3-BM, and B5/589 which were generously provided by Dr Jacalyn Pierce. Untransformed small airway epithelial cells from lung (SAEC) were purchased from Clonetics Corp. (Walkersville, MD, USA) and cultured in the manufacturer's SAGM medium. All cells were cultured in Dulbecco's Modi®ed Eagle Medium (D-MEM) supplemented with 10% fetal bovine serum (FBS), except for NIH3T3 and LnCAP which were grown in D-MEM containing 5% calf serum or RMPI 1640 with 10% FBS, respectively. Transfections were performed with the indicated expression constructs using LipofectAMINE Plus (Life Technologies, Grand Island, NY, USA) according to the manufacturer's speci®ca-tions.
Apoptosis assays
Viability and morphological parameters of apoptosis were assessed by monitoring changes in GFP marker expression from pTracer-SV40-derived vectors following transfection as described (Kasof et al., 2000) . The eects of Bcl-2, Bcl-x L , survivin and dominant negative FADD on protecting from DR6-mediated apoptosis were evaluated by co-transfection of equal amounts of each plasmid together with DR6 cDNA. In some instances, speci®c caspase inhibitors, Z-VAD-FMK, Z-DEVD-FMK, Z-IETD-FMK, Z-VEID-FMK, and Z-VDVAD-FMK (Enzyme Systems, Livermore, CA, USA) were added to the culture medium 3 h post-transfection at a concentration of 200 mM. Cells were ®xed with 2% paraformaldehyde in PBS, counterstained with 10 mg/ml propidium iodide, 200 mg/ml RNase A, and 0.1% Tween-20, and analysed for GFP levels using a laser scanning cytometer (LSC; CompuCyte, Cambridge, MA, USA) to quantify eects on apoptosis as described previously (Kasof et al., 2000) . Sample slides were also stained with Annexin-V Cy3 (Biosource International, Camarillo, CA, USA) to con®rm the morphological features of apoptosis.
Northern blotting
Poly(A)-RNA was prepared from the human tumor cell lines using the Poly(A) Pure kit (Ambion, Austin, TX, USA) following the manufacturer's speci®cations. Northern blotting was performed as described (Lorenzi et al., 1995) using 2 mg of poly(A) + RNA transferred onto nylon membranes. The membranes were ®rst hybridized to radiolabeled DR6 cDNA prepared using the Random Priming Labeling kit (Life Technologies, Grand Island, NY, USA) and incubated in Hybrisol I (Oncor, Gaithersburg, MD, USA) overnight at 428C. Membranes were then washed with 26 SSC+0.1% SDS at room temperature followed by high stringency washing, 0.16 SSC+0.1% SDS at 508C, and visualized by autoradiography. Following visualization of DR6 mRNA, membranes were stripped by standard methods and rehybridized to b-actin cDNA to normalize DR6 expression levels.
TaqMan
1 RT ± PCR analysis of DR6 mRNA expression DR6 protein and mRNA were measured in LnCAP and PC3 cells treated with TNF-a (Calbiochem, La Jolla, CA, USA), ibuprofen (Sigma, St. Louis, MO, USA), indomethacin (Biomol, Plymouth Meeting, PA, USA) and a peptide inhibitor of NF-kB nuclear translocation, SN50, or control peptide (Calbiochem, La Jolla, CA, USA). For mRNA expression, total RNA was isolated from the treated cells using RNA Stat-60 solution (Tel-Test, Inc., Friendswood, TX, USA) following the manufacturer's speci®cations. The quantitative ampli®cation of DR6 mRNA was carried out in a two-step RT ± PCR protocol with the TaqMan 1 Gold RT ± PCR kit (PE Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions. Synthesis of cDNA was prepared in a 50 ml reaction volume using 50 ng of total RNA and primed with random hexamers. The secondary PCR reaction was carried out in ABI Prism 7700 Sequence Detection System (PE Applied Biosystems, Foster City, CA, USA) using 10 ml of each primary reaction with either GAPDH¯uorescent probe and primer pair (PE Applied Biosystems, Foster City, CA, USA) or DR6¯uorescent probe (6FAM-AGGCCTC-GAATCT CATTGGCACATACC-TAMRA) and primer pair (forward primer 5'-CCA CAG CTC AGC CAG AAC AG-3'; reverse primer 5'-CGG TGG CAC GGT CAA CAT-3'). Serial dilution of each plasmid ranging from 1000 ± 1000 000 copies were used to generate standard curves of the ampli®cation reactions to quantify the data. The results of these analyses were expressed as the number of DR6 mRNA copies per 10 000 copies of GAPDH mRNA.
Tissue microarray
DR6 expression was analysed on tissue arrays from normal tissues and from prostate and breast cancer samples (Clinomics, Pitts®eld, MA, USA). The arrays were incubated with anity puri®ed rabbit anti-DR6 antibody followed by sequential incubations with a biotinylated anti-rabbit secondary antibody and peroxidase labeled strepavidin. The complex was visualized by a substrate-chromogen mixture containing 3,3'-diaminobenzidine (DAB) that produces a brown pigment observed by light microscopy. Negative controls substituted the DR6 antibody with rabbit nonimmune serum. Labeling was rated from 1 ± 5 and correlated with Gleason scores for prostate cancer.
Chromosomal localization
Genomic clones of DR6 were isolated by PCR screening pools of clones of a human genomic library in a bacterial arti®cial chromosome (BAC) vector (Genome Systems, St. Louis, MO, USA). Positive BAC clones were sequenced to con®rm the presence of DR6 exon and intron sequences and subsequently labeled with digoxigenin-dUTP by nick translation and used in¯uorescent in situ hybridization (FISH). FISH hybridization was performed on metaphase chromosomal spreads derived from PHA-stimulated peripheral blood leukocytes in a solution containing 50% formamide, 10% dextran sulfate and 26 SSC. Speci®c hybridization signals were detected by incubating the slides in¯uoresceinated antidigoxigenin antibodies followed by counterstaining with DAPI as described (Lorenzi et al., 1999) .
Antibody generation and immunoblotting
Rabbit polyclonal antibodies against the cytoplasmic domain of DR6 were prepared by Cambridge Research Biochemicals (Cleveland, UK) using bacterially expressed protein. E. coli BL21 containing GST-DR6 cytoplasmic domain expression construct were grown overnight and subsequently stimulated with 0.5 mM IPTG for 4 h. Lysates of bacterial pellets were incubated with 1% Triton X-100 for 30 min at 48C and centrifuged to remove insoluble material. Supernatants were added to a Glutathione Sepharose 4B column and bound protein was digested with PreScission protease (Amersham Pharmacia Biotech, Piscataway, NJ, USA) which cleaves at the junction between the GST and DR6 to thereby release the DR6 cytoplasmic domain from the column. Anti-DR6 antibodies were puri®ed further from whole serum of immunized rabbits using an anity matrix composed of DR6 cytoplasmic domain using standard methods.
Immunoprecipitation and Western blotting using anti-DR6 and commercial antibodies were performed as described previously (Lorenzi et al., 1996) . Commercial antibodies used included survivin (R&D Systems, Minneapolis, MN, USA), Bcl-2 (Biosource International, Camarillo, CA, USA), Bcl-x L (Biosource International, Camarillo, CA, USA), serine 32 phosphorylated IkB (New England Biolabs, Beverly, MA, USA), pan-IkB (New England Biolabs, Beverly, MA, USA), androgen receptor (Chemicon International, Inc., Temecula, CA, USA), and actin (Chemicon International, Inc., Temecula, CA, USA). Bound antibody on membranes was detected by chemiluminescence methods according to the manufacturer's speci®cations (ECL, Amersham Pharmacia Biotech, Piscataway, NJ, USA).
